Oral Cancer News – Page 275 – The Oral Cancer Foundation News Archive

Artists transform symbols of pain into objects of beauty

Source: Gazette.net Author: Jason Tomassini Radiation masks showcase courage of patients Lying on a table in Cookie Kerxton's tiny Bethesda art studio is a symbol of unparalleled pain and suffering: a white, plastic mask of her own face she wore during treatment for throat cancer. The loss of speech, being fed through her stomach, the severe dry mouth, the burns on her neck — the mask serves as a reminder of her lowest moments, spent strapped to an operating table with the mask covering her face and bolted to the table, the radiation blasting away at the malignant polyps that lined her throat. "You're only there for about 10 minutes," Kerxton, 73, said last week at the Upstairs Art Studio on St. Elmo Avenue. "But it's really not fun." When Kerxton beat her cancer, after four long months of chemotherapy in 2008, she wanted to keep the radiation mask, a bland but morbid piece of plastic that Kerxton said her friends call "ghoulish." Since, Kerxton gathered more than 100 radiation masks from area hospitals and found more than 100 artists from across the country to turn the masks into pieces of art, rather than symbols of pain. "It's taking something ‘ghoulish' and making it something someone would want to have on their wall," Kerxton said. In September, Kerxton's exhibit, called "Courage Unmasked," debuted before more than 500 people at a fundraiser and live auction at the Katzen Arts Center at American University. The roughly 40 masks still for sale will be exhibited starting [...]

Charlotte Parker2009-10-08T11:25:04-07:00October, 2009|Oral Cancer News|

British celebs back drive for new cancer treatment

Source: news.sky.com/skynews Author: staff Sir Alex Ferguson and Sir David Frost are among a host of celebrities giving their support to a cancer charity campaigning for a new type of treatment to be made available nationwide. The personalities are urging people to donate to medical trials of Photodynamic Therapy which, they say, could revolutionise cancer treatment in the UK and around the world. Killing Cancer (http://www.killingcancer.co.uk/) is aiming to raise £50m to fund further trials into Photo Dynamic Therapy, a treatment that tackles some forms of cancer by killing cells through a combination of drugs and light. The treatment is a form of laser that starves the cancer of oxygen, allowing the body to heal and create new, healthy cells. Its supporters say a single 20-minute session avoids the need for invasive surgery and the traumatic effects of chemotherapy and radiotherapy. It is also, they argue, cost-effective - for example, a skin cancer treatment would amount to just £235, far less than other more traditional treatments. Other well-known names supporting the charity include Chris Tarrant, Robert Plant, Jenny Seagrove and Roger Daltrey. They are sending more than 200 million personal emails to fans and supporters, asking for funds to be allocated to their choice of one of half a dozen PDT trials. "Both my mother and father died of cancer," said Manchester United manager Sir Alex. "I think PDT is an amazing first-step option before resorting to surgery. "More patients should have access to it in our hospitals [...]

Oral Cancer Foundation News Team - A2009-10-07T14:52:47-07:00October, 2009|Oral Cancer News|

Oropharyngeal cancer patients experience post-surgery sleep apnea

Source: Sciencecodex.com Author: Staff San Diego, CA – Nearly all patients who underwent surgery to treat oropharyngeal cancer experienced some degree of obstructive sleep apnea (OSA), according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA. The pilot study, which collected data from 22 patients treated for oropharyngeal cancer, found that among those who underwent primary surgery with free flap reconstruction, 93 percent had OSA as defined by a common measurement scale, with 67 percent defined as experiencing moderate or severe OSA (respiratory disturbance index greater than 15). Furthermore, 100 percent of those treated with radiation or chemotherapy (including some of the surgical group) developed OSA, although only one-third of these patients had moderate or severe OSA. The authors intend to continue their research with a larger pre-post treatment cohort study. They believe OSA may play a significant role in treatment related fatigue in this patient population. They also contend that unrecognized OSA may lead to additional comorbidity in this patient population, and the diagnosis and treatment of sleep apnea postoperatively may improve quality of life for these patients.

Charlotte Parker2009-10-07T11:44:16-07:00October, 2009|Oral Cancer News|

Understanding the link between HPV and oropharyngeal cancers

Source: www.jaapa.com (Journal of the American Academy of Physician Assistants, October, 2009) Authors: Denise Rizzolo, PA-C, PhD, Mona Sedrak, PA-C, PhD Head and neck cancer is diagnosed in approximately 650,000 patients each year worldwide.1 The term head and neck cancer refers to a group of biologically similar cancers originating from the upper aerodigestive tract, including the lip, oral cavity (mouth), nasal cavity, paranasal sinuses, pharynx, and larynx. Oropharyngeal refers to all the structures of the mouth and pharynx, including the tonsils and tongue. Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer.2 Seventy-five percent of all OSCCs are attributable to tobacco and alcohol use.3 People who smoke cigarettes are 4 times more likely to develop oral cancer than nonsmokers. Furthermore, individuals who consume alcohol are 3 times more likely than nondrinkers to develop oral cancer.3 According to the Substance Abuse and Mental Health Services Administration, the prevalence of cigarette smoking has decreased among Americans, and alcohol use has also declined since the 1970s.4,5 However despite this, the incidence of oropharyngeal cancers, including cancer of the base of the tongue and tonsils, has increased, especially in younger patients. These trends have led researchers to investigate other potential risk factors.6-8 New studies suggest that there may be an alternative pathway for the development of oropharyngeal cancers. The high-risk types of human papillomavirus (HPV), especially type 16 (HPV-16), are now thought to be potential etiologic agents.2,3 The concept that HPV plays a role in head and neck [...]

Oral Cancer Foundation News Team - A2009-10-06T22:00:20-07:00October, 2009|Oral Cancer News|

Big Tobacco still targets teenagers

Source: www.postbulletin.com Author: staff A couple of months ago I ran into a friend I hadn't seen in years. I didn't recognize him. A once solid and athletic guy, now in his late 40s, he'd lost more than 50 pounds and his skin was the color of fireplace ash. A long, thin scar ran from his jaw all the way down his neck and disappeared under his shirt. "I've got cancer," he said after re-introducing himself. He explained that he'd been through extensive surgery and treatments but that he was optimistic he'd pull through. Doctors told him smoking was the likely cause of his throat cancer. This week marks the two-year anniversary of the law that made it illegal to smoke in Minnesota's bars, restaurants and other public places. Olmsted County can take pride in the fact that it helped lead the way in the push to clear the air in the state's workplaces, eating establishments and watering holes. In November of 2001, Olmsted County Board members passed a comprehensive anti-smoking ordinance. The countywide ban was a courageous, landmark decision that helped create momentum for the statewide legislation. I don't know about you, but whenever I visit a state like Wyoming, where smoking is prohibited only in underground mines and other places where you could blow yourself up if you lit a match, I'm thankful for Minnesota's ban. It's so nice to be able to enjoy a meal without having to breathe in toxic fumes. But the tobacco wars continue. [...]

Oral Cancer Foundation News Team - A2009-10-06T21:04:12-07:00October, 2009|Oral Cancer News|

Nanomagnet in “Star-Trek style” wand could cure cancer

Source: www.telegraph.co.uk Author: staff The space-age technology, which uses microscopic iron particles to heat up and destroy tumours, may be ready for clinical trials in as little as three years. Different teams of UK scientists have been working together on the research, which could bring new hope to patients who are no longer responding to standard therapy. In future the ''nanomagnet'' cancer treatment may even be administered in GP surgeries or out-patient clinics. Crucially, the scientists believe it will be highly cost-effective. The technique literally ''cooks'' cancer cells as if they were in a microwave oven. But instead of microwaves, a rapidly changing magnetic field is generated by the paddle-shaped ''wand''. This heats up thousands of iron oxide ''nanoparticles'' placed inside the tumours. Heating the cells by only 5-6C is enough to send them into shock and kill them. Meanwhile, surrounding healthy tissue in which the iron oxide particles are absent is left unharmed. A major part of the research has involved finding ways to target tumours with the nanoparticles. Two approaches have been explored, one using bone marrow stem cells and the other using antibodies to ferry the particles to cancer sites. A major advantage of using a biological version of ''iron filings'' in the therapy is that they can easily be tracked by a magnetic resonance imaging (MRI) scanner. Doctors will be able to map exactly where the nanoparticles - and the cancer - are situated in the body. The ''wand'' can then be held over the hidden [...]

Oral Cancer Foundation News Team - A2009-10-06T20:29:12-07:00October, 2009|Oral Cancer News|

CDC finds poisons in dissolvable tobacco products

Source: Notobacco Author: Staff Since the beginning of this year, Indianapolis has been a test market for new dissolvable tobacco products, mostly from Camel. These are smokeless, spit-free, made from finely milled tobacco, and held together by food-grade binders. They look like breath mints, breath strips, or toothpicks, and are designed to be placed in the mouth, on the tongue or between the cheek and gum, where they dissolve to release tobacco. Dissolvable tobacco products are now available in Daviess County in the form of Stonewall dissolvable tablets. The manufacturer, Star Scientific, states that Stonewalls are designed for heavy smokers and spit tobacco users. This company also makes Ariva brand dissolvable tablets. Indiana Tobacco Prevention and Cessation agency feels the tobacco companies are illegally using Hoosiers as unwitting participants in a potentially dangerous clinical trial of these products since they were not tested for safety before being sold to the public, as food products, drugs, and cosmetics would be. Dissolvable tobacco products may contain up to three times the amount of nicotine found in one cigarette. A cigarette smoker typically takes in about 1 milligram of nicotine. Camel dissolvable products are said to deliver about 0.6 to 3.1 milligrams of nicotine each, Ariva tablets have about 1.5 millgrams of nicotine each, and Stonewall tablets have about 4 milligrams of nicotine each. People who use these products may get a higher dose of nicotine than they are used to, possibly resulting in nicotine poisoning, which manifests through adverse reactions such as tremors, [...]

Charlotte Parker2009-10-06T20:21:43-07:00October, 2009|Oral Cancer News|

Brazil develops medicine effective for rebuilding immune system

Source: news.xinhuanet.com Author: Fang Yang A team of Brazilian researchers is developing a medicine to treat AIDS, tuberculosis and cancerous tumors, according to an article published on Sunday's edition of Science, a magazine of Brazil' State of Sao Paolo University (UNESP). The medicine, known as P-Mapa, has shown signs of rebuilding immune systems in tests on animals and humans in Brazil, Chile and the United States, scientists said. P-Mapa has shown to trigger production of anti-tumor or anti-viral molecules in immune system cells, according to both Brazil's Emilio Ribas Institute and the U.S. National Institute of Allergies and Infectious Diseases (NIAID). "In all the tests performed to date, the drug has shown itself to be active and free of collateral or toxic side effects," said Iseu Nunes, director of Farmabrasilis, a non-government organization participating in the research. According to NIAID, the medicine is also effective in rats against Punta Toro, a virus which destroys their livers, outperforming traditional hepatitis C medicine. In addition, researchers are testing the medicine's effectiveness in fighting diabetes, osteoporosis and mouth cancer, with promising results. Researchers are expected to release the medicine and its profits will be invested in public health projects.

Oral Cancer Foundation News Team - A2009-10-06T06:51:00-07:00October, 2009|Oral Cancer News|

Curcumin may inhibit nicotine-induced activation of head and neck cancers

Source: www.sciencedaily.com Author: staff Curcumin, the compound that gives curry powder its yellow/orange color, may inhibit the adverse effects of nicotine in patients with head and neck cancer who continue to smoke. In a paper presented at the 2009 American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO in San Diego, researchers examined the effects of curcumin on head and neck squamous cell carcinoma (HNSCC) growths. The study used an in vitro model of a variety of head and neck cancer cell lines. To mimic the clinical situation, HNSCC cells were pre-treated with curcumin and then nicotine was introduced. The results of the studies showed that the curcumin was able to block the nicotine from activating cancer causing cells. Annually there are approximately 40,000 new cases of head and neck cancers and 13,000 deaths in the U.S. and 500,000 new cases worldwide. Recurrence of these cancers are high because many patients continue to smoke after successful treatment. Also, former smokers often use nicotine replacement therapy as an aid for successful tobacco cessation. Although nicotine itself has not been shown to be carcinogenic, it has been shown to encourage the cancer-forming process. The researchers sought a safe, bioactive food compound that could be used not only as a chemopreventive agent but could also block the harmful effects of nicotine. The results may help to discover additional therapies for cancer prevention and treatment. Note: 1. Adapted from materials provided by American Academy of Otolaryngology -- [...]

Oral Cancer Foundation News Team - A2009-10-05T05:04:07-07:00October, 2009|Oral Cancer News|

Oncolytics’ Phase III borrows adaptive design in SPA trial

Source: www.bioworld.com Author: Catherine Hollingsworth Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. The Phase III trial will be conducted in two stages and will cost an estimated $15 million, Matt Coffey, Oncolytics' chief operating officer, told BioWorld Today. The Calgary, Alberta-based company has the cash to get through the first half of the study on its own, but it hopes to secure a partner to take Reolysin the rest of the way, he said. The trial uses an adaptive design in which "the endpoint is not fixed going in," CEO Brad Thompson said during a conference call. He said it was "a major advantage" getting the FDA to sign off on the study design up front under a special protocol assessment. Thompson said that the adaptive design already is in use in the area of infectious disease, and he said he believes that there will be "a big push" by the FDA for more adaptive trials to be conducted in oncology. The trial will assess the intravenous administration of Reolysin with the chemotherapy combination of paclitaxel and carboplatin vs. chemotherapy alone. The drug likely will be studied in about 275 patients whose cancer has progressed while on or after prior platinum-based chemotherapy. The first stage of the trial is nonadaptive and is designed to enroll 80 patients. The second stage is adaptive, and [...]

Oral Cancer Foundation News Team - A2009-10-05T04:59:16-07:00October, 2009|Oral Cancer News|